A Phase 1 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
Clinical Trial Grant
Awarded By
Numab Therapeutics AG
Start Date
August 13, 2024
End Date
August 11, 2029
Awarded By
Numab Therapeutics AG
Start Date
August 13, 2024
End Date
August 11, 2029